News

Evotec has posted a net loss of EUR1.2m for the first quarter 2010, or EUR 0.01 per diluted share, compared to EUR21.8m, or EUR 0.21 per diluted share,

On May 7, 2010, IntelGenx executed a project transfer agreement with Cary Pharmaceuticals, its former development partner, whereby Cary assigned its 50% ownership stake in CPI-300 to IntelGenx.

Suven said that the granted claims of the patents include the class of selective 5-HT compounds discovered by it and are being developed as therapeutic agents and are

Following the approval from the FDA, Aeterna Zentaris expects to initiate a Phase 2 clinical trial in this indication in the second half of this year. The study

As per the agreement, Abbott is expected to gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a growing presence. The

Novus Biologicals said that this new kit allows researchers to use any antibody, regardless of the buffer or concentration, with Lightning Link Kits. Antibodies are sometimes only available

Sanofi-aventis said that the rationale of the trial was based on post-hoc findings from the Athena trial, in which a trend towards reduction of CV hospitalisation and death

PLx Pharma claimed that the other grants NIH has awarded to it in the recent months include The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

According to the Alnylam, the new study performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics and AlCana Technologies, described a